Latest Pharmacology (medical) research

Top 10 this week

Week of 20 September 2026

1. 1

   Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

   Frontiers in pharmacology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 31 August 2026

   Meta‑analysis of SGLT2 inhibitors, efficacy focus

2. 2

   Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

   Frontiers in pharmacology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 3 September 2026

   A meta-analysis of 19 randomized trials involving 38,160 patients found that semaglutide use was linked to a 19% higher odds of any neoplasm and a 28% higher odds of benign tumors, while the increase in malignant cancers did not reach statistical significance. Clinicians should stay alert to these modest risks, and longer trials are needed to determine their true clinical impact.

3. 3

   Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials

   European journal of clinical pharmacology · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 16 September 2026

4. 4

   Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Adult Traumatic Brain Injury: A Systematic Review and Meta-Analysis

   Neurosurgery · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 14 September 2026

5. 5

   Prasugrel in the management of acute coronary syndromes: a systematic review

   Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 17 September 2026

6. 6

   Efficacy and Tolerability of Zonisamide for Alcohol Use Disorder: A Systematic Review and Meta-Analysis

   Journal of clinical psychopharmacology · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 18 September 2026

   Zonisamide for alcohol use disorder, efficacy rather than PK/PD

7. 7

   Improving Medication Safety in Chronic Kidney Disease Using Rule-Based and Artificial Intelligence-Based Clinical Decision Support Systems: A Systematic Review of Randomized Controlled Trials

   F1000Research · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 28 August 2026

   A systematic review of 20 randomized trials found that rule-based or AI-driven decision support increased the rate of correctly dosed kidney-related medications (about 1.8-fold higher) compared with usual care, though results varied widely across settings. Documentation of CKD in electronic records also improved by about 20%, but alert fatigue limited clinician compliance, leaving real-world effectiveness uncertain.

8. 8

   Minor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies

   Pain · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 14 September 2026

   Meta-analysis of endogenous opioids, not PK/PD

9. 9

   Traditional, complementary, and integrative medicine therapies for mild/moderate acute COVID-19: a systematic review and network meta-analysis

   Phytomedicine : international journal of phytotherapy and phytopharmacology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 27 August 2026

10. 10

    Treatment shortening and relapse control in drug-susceptible pulmonary tuberculosis: a network meta-analysis of randomized trials

    Frontiers in cellular and infection microbiology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 3 September 2026

    TB treatment shortening meta‑analysis, not PK/PD

Paper of the day, last two weeks

• MTHFR C677T TT genotype associated with poor blood pressure control in H-type hypertension without folic acid: a retrospective cohort study

  Frontiers in pharmacology · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 4 September 2026

  MTHFR C677T genotype and BP control without folic acid

• Menthol for the Relief of Dyspnea: A Systematic Review of Randomized Controlled Trials

  Lung · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 18 September 2026

  Systematic review of menthol RCTs for dyspnea

• Repeated voriconazole therapeutic drug monitoring in hospitalised patients: a real-world cohort study of out-of-range exposure and concentration response to dose adjustment

  Frontiers in pharmacology · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 2 September 2026

  Repeated voriconazole TDM, out‑of‑range exposure factors

• Repeated voriconazole therapeutic drug monitoring in hospitalised patients: a real-world cohort study of out-of-range exposure and concentration response to dose adjustment

  Frontiers in pharmacology · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 2 September 2026

  Repeated voriconazole TDM, out‑of‑range exposure factors

• Bioavailability of a novel anti-influenza agent, onradivir granules, in healthy Chinese adults: a first-in-human study

  Frontiers in pharmacology · Q1 journal · Non-randomized trial · Evidence level 2 (Moderate) · 1 September 2026

  Onradivir granules bioavailability study, PK focus

• Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis

  Advances in therapy · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 15 September 2026

  Evinacumab lipid‑lowering meta‑analysis

• Safety Profile of the Non-steroidal Anti-inflammatory Drug Celecoxib in the Short-Term Management of Acute Non-cancer Pain: A Systematic Review with Meta-analysis of Randomised Controlled Trials

  Drugs · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 12 September 2026

  In a meta-analysis of 50 trials with over 10,000 patients, short-term celecoxib (200-400 mg daily up to 10 days) showed about a 66% lower risk of gastrointestinal adverse events compared with opioids, and modestly fewer nausea episodes than placebo or non-selective NSAIDs. Evidence certainty was very low, so clinicians should weigh these findings against individual patient risk.

• Development of a dosing algorithm integrating pharmacogenetic markers and inflammation for individualization of initial voriconazole maintenance doses

  Antimicrobial agents and chemotherapy · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 11 September 2026

  Voriconazole dosing algorithm integrating pharmacogenetics and inflammation

• Development of a dosing algorithm integrating pharmacogenetic markers and inflammation for individualization of initial voriconazole maintenance doses

  Antimicrobial agents and chemotherapy · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 11 September 2026

  Voriconazole dosing algorithm integrating pharmacogenetics and inflammation

• Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

  CPT: pharmacometrics & systems pharmacology · Q1 journal · RCT · Evidence level 1 (High) · 1 September 2026

  Population PK model informs dosing in TB drug development clinical

• A prospective pharmacokinetic interaction study between rifampicin and fusidic acid for the treatment of staphylococcal infections

  The Journal of antimicrobial chemotherapy · Q1 journal · RCT · Evidence level 1 (High) · 1 September 2026

  Rifampicin‑fusidic acid PK interaction study

• Unlocking the Potential of Auricular Therapy: A Promising Solution for Lumbar Disc Herniation Pain

  Pain research & management · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 1 January 2026

• Comparative pharmacotherapeutic efficacy and dose-related safety profiles of intrathecal baclofen: a systematic review and meta-analysis in neurological spasticity

  Frontiers in pharmacology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 24 August 2026

  Systematic review, dose‑response safety of intrathecal baclofen